Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marie-Paule Sablin

Showing results (11-20 of 51) with videos related to

Pageof 6
Sort By:
Bulletin Du Cancer|January 28, 2017
[Cell cycle inhibitors in endocrine receptor positive breast cancer]Marie-Paule Sablin, Francesco Ricci, Delphine Loirat, et al.
European Journal of Cancer (Oxford, England : 1990)|November 22, 2013
Ocular adverse events of molecularly targeted agents approved in solid tumours: a systematic reviewOlivier Huillard, Silvin Bakalian, Christine Levy, et al.
Investigational New Drugs|December 15, 2018
Phase I dose-escalation study of F14512, a polyamine-vectorized topoisomerase II inhibitor, in patients with platinum-refractory or resistant ovarian cancerAlexandra Leary, Christophe Le Tourneau, Andrea Varga, et al.
World Journal of Hepatology|May 5, 2015
Disease control with sunitinib in advanced intrahepatic cholangiocarcinoma resistant to gemcitabine-oxaliplatin chemotherapyChantal Dreyer, Marie-Paule Sablin, Mohamed Bouattour, et al.
Personalized Medicine|May 16, 2018
Challenges for the implementation of high-throughput testing and liquid biopsies in personalized medicine cancer trialsLoic Verlingue, Marie Alt, Maud Kamal, et al.
Cancer Chemotherapy and Pharmacology|September 14, 2014
Clinical study of the novel cyclin-dependent kinase inhibitor dinaciclib in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia patientsClaire Fabre, Marco Gobbi, Cyrine Ezzili, et al.
Oncotarget|September 9, 2017
Cabazitaxel in recurrent/metastatic squamous cell carcinoma of the head and neck: phase II UNICANCER trial ORL03Jerome Fayette, Joel Guigay, Christophe Le Tourneau, et al.
Cancer Immunology, Immunotherapy : CII|February 9, 2020
The fully synthetic glycopeptide MAG-Tn3 therapeutic vaccine induces tumor-specific cytotoxic antibodies in breast cancer patientsPierre Rosenbaum, Cécile Artaud, Sylvie Bay, et al.
Plos One|December 20, 2015
Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant ChemotherapyHélène Bonsang-Kitzis, Léonor Chaltier, Lisa Belin, et al.
JCO Precision Oncology|February 1, 2022
Comparative Analysis of Durable Responses on Immune Checkpoint Inhibitors Versus Other Systemic Therapies: A Pooled Analysis of Phase III TrialsElvire Pons-Tostivint, Aurélien Latouche, Pauline Vaflard, et al.
Pageof 6

Showing results (11-20 of 51) with videos related to

Sort By:
Pageof 6
Bulletin Du Cancer|January 28, 2017
[Cell cycle inhibitors in endocrine receptor positive breast cancer]Marie-Paule Sablin, Francesco Ricci, Delphine Loirat, et al.
European Journal of Cancer (Oxford, England : 1990)|November 22, 2013
Ocular adverse events of molecularly targeted agents approved in solid tumours: a systematic reviewOlivier Huillard, Silvin Bakalian, Christine Levy, et al.
Investigational New Drugs|December 15, 2018
Phase I dose-escalation study of F14512, a polyamine-vectorized topoisomerase II inhibitor, in patients with platinum-refractory or resistant ovarian cancerAlexandra Leary, Christophe Le Tourneau, Andrea Varga, et al.
World Journal of Hepatology|May 5, 2015
Disease control with sunitinib in advanced intrahepatic cholangiocarcinoma resistant to gemcitabine-oxaliplatin chemotherapyChantal Dreyer, Marie-Paule Sablin, Mohamed Bouattour, et al.
Personalized Medicine|May 16, 2018
Challenges for the implementation of high-throughput testing and liquid biopsies in personalized medicine cancer trialsLoic Verlingue, Marie Alt, Maud Kamal, et al.
Cancer Chemotherapy and Pharmacology|September 14, 2014
Clinical study of the novel cyclin-dependent kinase inhibitor dinaciclib in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia patientsClaire Fabre, Marco Gobbi, Cyrine Ezzili, et al.
Oncotarget|September 9, 2017
Cabazitaxel in recurrent/metastatic squamous cell carcinoma of the head and neck: phase II UNICANCER trial ORL03Jerome Fayette, Joel Guigay, Christophe Le Tourneau, et al.
Cancer Immunology, Immunotherapy : CII|February 9, 2020
The fully synthetic glycopeptide MAG-Tn3 therapeutic vaccine induces tumor-specific cytotoxic antibodies in breast cancer patientsPierre Rosenbaum, Cécile Artaud, Sylvie Bay, et al.
Plos One|December 20, 2015
Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant ChemotherapyHélène Bonsang-Kitzis, Léonor Chaltier, Lisa Belin, et al.
JCO Precision Oncology|February 1, 2022
Comparative Analysis of Durable Responses on Immune Checkpoint Inhibitors Versus Other Systemic Therapies: A Pooled Analysis of Phase III TrialsElvire Pons-Tostivint, Aurélien Latouche, Pauline Vaflard, et al.
Pageof 6